Skip to main content

Marina Inks Partnership for Bladder Cancer Program

Premium

Marina Biotech said this week that it has signed an exclusive deal to work with Swiss biopharmaceuticals group Debiopharm to develop and commercialize its preclinical bladder cancer program.

Under the terms of the deal, the companies will work together to advance the RNAi drug candidate, but Debiopharm will have “full responsibility for the development and commercialization of any products arising from the partnership.” Marina stands to receive up to $25 million based on “predefined research and development milestones,” as well as royalties on product sales, the firms said.

Additional terms were not disclosed.

Bladder cancer had been Marina's lead program, with the company anticipating a phase I study as early as 2012 (GSN 13/25/2010). However, when it acquired Cequent Pharmaceuticals last year, that company's investigational treatment for familial adenomatous polyposis, which is expected to enter the clinic this year, moved to the forefront (GSN 11/18/2010).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.